Eisai has discontinued one Phase III development project and dropped several others at Phase II as it reorganises R&D priorities against a background of sharply lower sales of its once blockbuster Alzheimer's disease product Aricept (donepezil).
Global sales of the acetylcholinesterase inhibitor dwindled to ¥147.1 billion ($1.84 billion) in the fiscal year ended 31 March, a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?